Complexes of IL-15 and IL-15Ralpha and uses thereof
AssigneesNovartis AG, The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsBarbara K. Felber, Sergio Finkielsztein, George N. Pavlakis, John V. Vournakis
Life of this patent
Estimating the term…
Abstract
The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol” those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-β-1-♦4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.
Claims4
A method of recombinantly producing a human IL-15 and a human IL-15Ra complex, comprising:
- (a) culturing a cell expressing a human IL-15 encoded by a nucleic acid sequence with at least 95% identity to nucleic acid residues 1 to 489 of SEQ ID NO:2;
- and a human IL15Ra encoded by:
- (i) a nucleic acid sequence with at least 95% identity to nucleic acid residues 1 to 804 of SEQ ID NO:5;
- or (ii) a nucleic acid sequence with at least 95% identity to nucleic acid residues 1 to 615 of SEQ ID NO:6 and
- (b) purifying the human IL-15 and human IL-15Ra complex,
- wherein the cell expresses at least 150 ng/million cells of human IL-15 per day when cultured in serum-free media.
Dependencies are inferred from the claim text.